Agilent Technologies, Inc. (A)
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Last price
- $174.00
- As of
Kresmion compiles this page from A's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AGILENT TECHNOLOGIES, INC. (A): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
See the full A dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for A on one page. Preview it with sample data, then open it live with a free account.
Preview the A dossierActive signals for A
- mediumHIGH_RATE_ISSUANCE
Bond issued at elevated rate 4.9%, above the credit-stress threshold
- highCONSENSUS_SELL
4 tracked funds reduced A this 2026Q2, institutional consensus
- mediumEARNINGS_BEAT
Q3-2026: Beat consensus by 6.9%, EPS $1.62 vs $1.5154 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +96% to A (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +571% to A (2026Q2)
FREE, NO ACCOUNT
Every signal on A, as it fires
You are seeing 5 of 31 signals recorded on A since 2026-05-05.
The five above landed across 4 days. The other 26 were recorded on 3 other days. 26 of the 31 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in A (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 00846U101 · 2026Q2 | $197.4M | 0.09% | , |
| CITADEL ADVISORS LLCCUSIP 00846U101 · 2026Q2 | $146.3M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 00846U101 · 2026Q2 | $12.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00846U101 · 2026Q2 | $3.1M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 00846U101 · 2026Q2 | $3M | 0.01% | , |
| GREENHAVEN ASSOCIATES INCCUSIP 00846U101 · 2026Q2 | $1.4M | 0.02% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, A
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
A mentioned in Kresmion daily briefs
A against its peers
A's operating margin of 21.3% ranks in the 94th percentile of 23 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | A | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 6.9B USD | 1.2B USD | 87 | 25 |
| Gross margin | n/a | 57.3% | n/a | 12 |
| Operating margin | 21.3% | -3.8% | 94 | 23 |
| Net margin | 18.8% | -3.6% | 87 | 25 |
| Return on equity | 19.3% | -5.0% | 82 | 24 |
| P / E | 38.1x | 44.5x | 21 | 11 |
| 1 year | 26.1% | 28.0% | 44 | 25 |
Peers (25): IQV, WAT, ILMN, MTD, MEDP, DHR, CRL, TEM, TECH, RGEN, AVTR, TXG, TMO, BRKR, SHC, ADPT, ABCL, FTRE, MRVI, DNA, MLAB, CTKB, OABI, PACB, CDXS. Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (A: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow A on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to A for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.